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Normal T cells play a critical role in the r egulation of 
humoral immune responses by acting as potentiators 
(helper cells) or inhibitors (suppressor cells) of the proc-
ess by which B cells differentiate into immunoglobulin-
secreting plasma cells. Certain diseases in which malig-
nant T cells appear to retain an immunoregulatory nmc-
tion are characterized by a propensity of a lymphoma-
tous T-cell population to infiltrate skin. Some cutaneous 
T -cell lymphomas, as well as some T -cell neoplasms 
without dermatologic involvement, provide a homoge-
neous supply of T lymphocytes which act as immuno-
regulators. The availability of neoplastic T cells with 
immunoregulatory properties could accelerate the sero-
logic and biochemical analysis of the cellular control of 
normal immunity in man. 
Recent insights into the cellular control of immune responses 
may become important to physicians who treat patients with a 
variety of dermatologic disorders. Moreover, as will be discussed 
below, such physicians often have the first clinical opportunity 
to recognize pat ients with neoplasms that may potentially be 
derived from immunoregulatory T cells and can thus provide a 
basic resow-ce in investigating the regulation of human immune 
reactions. 
Bone marrow lymphocyte precw-sor cells may develop ac-
cording to 2 pathways of matw-ation, one involving B cells 
responsible for mediating humoral immune responses and an-
other involving T cells responsible for mediating cellular im-
mune responses. The first precursor cell that can be identified 
as committed to the B cell/plasma cell series contains small 
amounts of cytoplasmic IgM without easily detectable sw-face-
membrane-bound immunoglobulin. These· precw-sor cells, 
which have been referred to as pre-B cells, fu·st appear in the 
fetal liver and later reside predominantly in the bone marrow 
[1,2]. Pre-B cells develop into immature B cells (small lympho-
cytes with a single immunoglobulin isotype-IgM-on their 
sw-face) and then into mature B cells. Mature B cells can be 
identified as cells with a series of sw-face membrane receptors 
including receptors for antigen-antibody complexes, comple-
ment components, certain plant lectins (such as pokeweed 
mitogen) , and membrane-bound lgM and IgD (or other im-
munoglobulins) that have the same antigen-binding portions 
(variable regions) as the immunoglobulin molecules ultimately 
secreted by their plasma cell progeny. 
The precursor lymphocytes that undergo differentiation in 
the micro-environment of the thymus ru·e called T cells. In 
certain models, thymic epithelial cells play a direct par t in 
selecting the ultimate recognition capacity of maturing T cells 
[3]. T cells mediate the classic reactions of cellular immunity, 
including delayed hypersensitivity, allograft rejection, graft-ver-
sus-host reactions, lysis of virus-infected target cells and direct 
tumor-cell killing in some systems. 
Although T cells may express antigen-binding receptors that 
have the same (or very similar) variable regions as the variable 
regions associated with immunoglobulin heavy chains [4-6], 
normal T cells do not produce conventional immunoglobulins. 
However, T cells do have a crucial role in the regulation of 
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humoral immune responses by acting as potentiators or inhib-
itors of the B-cell transition into immunoglobulin-secreting 
plasma cells. The cells that potentiate this B-cell transition are 
classified as helper cells, whereas those that inhibit it ru·e 
classified as suppressor cells. 
There is compelling evidence in mice [7], and corroborating 
evidence in human beings [8,9], that help and suppression are 
mediated by distinct subsets ofT cells, each genetically com-
mitted to mediate only one of these 2 functions. In mice, helper 
T-cell and suppressor T-cell subsets can be readily distin-
guished by their so-called Ly surface-membrane antigens. Im-
munoregulatory T cells may have an interim existence as in-
active precw-sor cells, which might be referred to as pro-helper 
cells and pro-suppressor cells [10-12]. T hese immunoregulatory 
precw-sor cells must interact with a different set of activator T 
cells before matw-ing into fully functional helper effector cells 
or suppressor effector cells. Both antigen-specific and nonspe-
cific T-cell regulatory controls exist. Furthermore, T-cell regu-
latory control may be exerted upon the production of all im-
munoglobulin isotypes (classes), a single immunoglobulin iso-
type, a single immunoglobulin allotype, or even a single idi-
otype. Accessory cells which belong to the monocyte-macro-
phage series are also extremely important in a wide range of 
regulatory T -cell to B-cell as well as T -cell toT -cell interactions. 
A great deal of knowledge about the natw-e of the humoral 
immune response in man was made possible by studying neo-
plasms of the B-cell/ plasma cell series. The recognition that so-
called paraproteins derived from patients with multiple mye-
loma represent extremely homogeneous immunoglobulins was 
an indispensable step in understanding the structural, func-
tional, m etabolic, and genetic aspects of humoral immunity. 
Malignancies ofT-cell origin are of exceptional interest because 
in some cases the neoplastic T cells may retain an immunoreg-
ulatory capacity. For reasons which ru·e not cleru·, a good many 
patients whose neoplastic T cells appear to retain an immuno-
regulatory function have diseases ch ru·acterized by cutaneous 
infiltration with malignant cells. 
The study of neoplastic T cells (and their soluble products) 
could eventually be as rewru·ding in resolving questions regard-
ing cellulru· immunity, and especially the cellular control of 
immunoglobulin production, as myeloma and its paraprotein 
products have proved to be in resolving questions concerning 
humoral in1munity. In this paper, we shall describe the use of 
neoplastic cells from a vru·iety of patients as a resow-ce m 
studying human immunoregulatory T-cell functions. 
METHODS FOR THE IN VITRO STUDY OF 
POLYCLONAL HELPER AND SUPPRESSOR T-CELL 
ACTIVITY 
Detection of Immunoglobulin Synthesis by Lymphocytes in 
Vitro 
To study the terminal differentiation of circulating lympho-
cyte populations into immunoglobulin-secreting plasma cells 
under conditions of polyclonal activation, cells were cultured in 
the presence of pokeweed mitogen for 7 to 12 days. At the 
termination of the culture period, the amount of IgM, IgG, and 
lgA synthesized and secreted into the medium was determined 
by heavy chain specific double antibody radioimmunoassays. 
This methodology has been described in detail previously 
[13]. There ru·e other polyclonal activators for immunoglobulin 
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production by human lymphocytes in vitro (for example, a 
water-soluble extract from Nocardia opaca as well as Epstein-
Barr virus), but these agents may function differently from 
pokeweed mitogen, which is a highly T-cell-dependent B-cell 
activating agent. It is important to stress that in anticipating 
the human B-cell stimulatory properties of any polyclonal 
activator, one cannot simply extrapolate from the experience 
using murine systems. 
Preparation of Normal T-cell and B-cell Populations 
Many of the studies described in this paper required indicator 
B cells which were rigorously depleted ofT cells. We prepared 
T cells and populations of B cells depleted ofT cells by a 2-step 
procedure predicated on the observation that normal T cells 
pass through anti-F(ab'h immunoabsorbent columns and form 
spontaneous rosettes with sheep red blood cells (SRBCs). On 
the other hand, normal B cells are selectively retained by 
immunoabsorbent columns (from which they may be eluted) 
because of their surface-bound immunoglobulin molecules, and 
do not form spontaneous rosettes with SRBCs. These methods 
have been described in detail previously [8]. 
Assays of Helper Cell Activity 
As mentioned above, pokeweed mitogen is aT-cell-dependent 
polyclonal stimulator of immunoglobulin secretion. In opera-
tional terms, this means that pokeweed mitogen-driven human 
B cells, rigorously freed of T cells, secrete only very small 
quantities of immunoglobulin. The capacity of added cells to 
augment immunoglobulin secretion by such normal B cells may 
be used as a test for helper activity. This is a test for antigen 
nonspecific helper function. Unlike certain antigen-specific 
helper cell assay systems in mice, this pokeweed mitogen-driven 
helper T -cell assay does not exhibit rigid T /B histocompatibil-
ity restrictions. 
Assays of Suppressor Cell Activity 
The presence of suppressor cells was detected by a co-cultme 
technique. Circulating cells from patients undergoing study and 
circulating lymphocyte populations from normal subjects were 
co-cultured together in the presence of pokeweed mitogen 
(13]. The secretion of immunoglobulin by cells from the 2 
subjects in co-culture was related to the sum of the expected 
contribution by each cell population. lgM, IgG, and lgA pro-
duction by mixtures of allogeneic lymphocytes from normal 
individuals ranged from 95 to 106% of the expected value. We 
considered a depression· of immunoglobulin production in the 
co-cultme system to less than 50% of the expected value to 
signify a suppressor cell effect. This assay is a test for antigen 
nonspecific suppressor activity. 
HELPER CELL NEOPLASMS 
The S ezary Syndrome 
The Sezary syndrome is a very serious disorder characterized 
by an exfoliative erythroderma, generalized lymphadenopathy, 
and a leukemia of cells which have a marked propensity to 
infiltrate the epidermis [14]. These leukemic cells have a cere-
briform (deeply folded) nucleus, and are referred to as Sezary 
cells. In the epidermis, the neoplastic cells may form distinctive 
nests known as Pautrier's microabscesses. Skin biopsies from 
patients with th~Sezary syndrome are essentially indistinguish-
able from those of patients with mycosis fungoides. Based on 
the capacity to form spontaneous SRBC rosettes and suscepti-
bility to lysis in the presence of complement and heterologous 
antisera raised against thymic lymphocyte antigens, Sezary 
cells from most patients studied are thought to have a T-cell 
origin. 
The Sezary syndrome and mycosis fungoides fit into the same 
spectrum of diseases in terms of clinical, histologic, cytologic, 
and immunologic presentation. While there may be practical 
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clinical considerations for drawing distinctions between these 2 
entities, it is worth emphasizing that overt transitions are 
common. For many research purposes, it is extremely useful to 
consider these entities as comprising a unified cutaneous T-cell 
lymphoma syndrome. 
In 1966, Blaylock et al [15] provided what might have been 
one of the first clues that some patients with cutaneous T-cell 
lymphomas might have a neoplasm which represents an expan-
sion of cells with an immunoregulatory capacity. These inves-
tigators observed that many patients with what would now be 
considered a cutaneous T -cell lymphoma syndrome had ex-
ceedingly high serum levels of IgA. lgA is an important immu-
noglobulin which is found both in serum and external secretions. 
There is a large body of data to suggest that those B cells which 
ultimately matme into lgA-secreting plasma cells depend heav-
ily on T -cell helper influence before final maturation can occm 
[16]. Thus, the striking elevation of a highly thymic-dependent 
isotype might have been the first indication that the neoplastic 
lymphocytes found in certain patients with cutaneous T-cell 
lymphoma had retained an important immunoregulatory func-
tion. Moreover, there have been reports of patients with the 
Sezary syndrome who developed monoclonal serum immuno-
globulin abnormalities [17-20]. Monoclonal IgM, IgG, and IgA 
serum abnormalities have been documented. It is conceivable 
that such examples of excessive B-cell activity could represent 
the in vivo expression of overactive helper T -cell function. 
There is a real possibility that certain subsets of neoplastic T 
cells can express helper activity for a specific B-cell clone (so-
called idiotype-speciflc helper function), while other neoplastic 
T-cell subsets can express polyclonal B-cell helper activity. 
Results in om own laboratory over the past 3 yr have led us 
to conclude that some patients with the Sezary syndrome 
varient of cutaneous T-celllymphoma may have a disease that 
represents a homogeneous expansion of polyclonal helper T 
cells. As previously discussed, normal human lymphocytes may 
be induced to produce immunoglobulins in vitro in the presence 
of pokeweed mitogen. The production of immunoglobulins by 
human lymphocytes in the presence of pokeweed mitogen is a 
highly T-cell-dependent process. 
It is worth emphasizing that stringent standards must be 
applied before a helper activity can be assigned to any given 
neoplastic population of cells. In some cases, indicator normal 
B-cell populations will produce normal (or nearly normal) quan-
tities of immunoglobulin following stimulation with pokeweed 
mitogen in vitro when there is as little as a 2% contaminating 
population of normal T cells present. Therefore, in studying the 
helper activity of neoplastic lymphocytes a special effort to 
exclude the effects of contaminating residual normal T cells is 
necessary. In our studies of patients with the Sezary syndrome, 
we were able to select patients with extremely high T-leukemic 
counts. This provided us with a starting "biologic" purification. 
In addition, when the neoplastic lymphocytes of a patient 
appeared to mediate a helper effect (using an " undiluted" 
sta1ting system for helper activity which involved 1.0 X 106 
neoplastic T cells cultured with 5.0 X 105 normal indicator B 
cells), we studied the capacity of dilutions of the patients' cells 
to mediate "help" when co-cultured with normal B cells. We 
categorized the neoplast ic cells as helper cells if they augmented 
pokeweed mitogen-driven normal B-cell immunoglobulin secre-
tion using a ratio of 5 B cells to one T cell (5 X 105 normal 
indicator B cells in culture with 1 X lOr' neoplastic cells). We 
have studied the neoplastic cells from 15 patients with the 
Sezary syndrome. 
Using the guidelines described above, approximately 50% of 
our patients with Sezary's syndrome tested had peripheral 
blood neoplastic T cells which retained an in vitro helper 
activity. There was a 6-fold to >30-fold augmentation of im-
munoglobulin synthesis and secretion by normal B cells when 
co-cultured with Sezary cells derived from these patients. In 
addition, Sezary cells from one patient studied induced nearly 
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a 10-fold increase in IgA synthesis by lymphocytes obtained 
from a child with ataxia telangiectasia and isolated IgA defi-
ciency. Moreover, these same Sezary cells induced a >500-fold 
increase in IgA and lgG secretion by lymphocytes from a child 
with a severe congenital thymic deficiency (N ezelof's syn-
drome) [8]. These studies cannot be explained on the basis of 
a simple allogeneic effect since the neoplastic Sezary cells which 
exerted the helper effect when co-cultured with lymphocytes 
from the child with ataxia telangiectasia and the child with 
N ezelof's syndrome neither stimulated nor responded in mixed 
leukocyte-reaction tests. 
We recently studied a patient with the Sezary syndrome who 
secondarily acquired an aggressive lymphoma, histologically 
classified as a T-cell immunoblastic sarcoma. Although the 
lymphomatous cells formed spontaneous SRBC rosettes (and 
could thus be classified as having aT-cell origin), they did not 
have the typical cerebriform nuclei associated wit h Sezary cells, 
but rather, had round to oval nuclear contours. Nonetheless, 
these lymphomatous cells could mediate a helper T-cell func-
tion [21]. We have also observed one infant with acute lympho-
blastic leukemia who had neoplastic T cells which appeared to 
mediate a helper effect. (However, most patients with acute 
lymphoblastic leukemia do not have cells with detectable im-
munoregulatory activity.) These observations strongly suggest 
that neoplastic T cells from disease states other than the Sezary 
syndrome may eventually be found to mediate a helper-cell 
immunoregulatory activity . Of interest, Roder et al [22] have 
concluded that the permanently transformed T cells of a murine 
leukemia line (485-2) maintain a carrier-specific type of helper 
activity under condit ions of antigen-activation. We shall return 
to other systems in mice that provide added insights about 
neoplasms of immunoregulatory T cells later in this article. 
SUPPRESSOR CELL NEOPLASMS 
Subacute T -Cell Leukemia in Japan 
Recently, the clinical and hematologic features of an appar-
ently new kind of adul t T-cell leukemia were described by 
Uchiyama and co-workers [23]. This disease has several inter-
esting features. It occurs in adults. There is generally a subacute 
leukemic course with a rap idly progressive terminal phase. The 
leukemic cells form spontaneous SRBC rosettes and can be 
killed by heterologous antisera against human T-cell membrane 
antigens. Moreover, the leukemic T cells in this syndrome 
frequently have lobulated nuclei (under electron microscopic 
examination, however, the nuclei are generally not as convo-
luted as those of typical Sezary cells). There is frequent leu-
kemic involvement of the dermis and subcutaneous layers; 
however, true epidermal infiltration and the formation of Pau-
trier's microabscesses, as might be seen in the Sezary syndrome, 
are distinctly unusual. Of note, lymphadenopathy and hepato-
splenomegaly are common. These patients do not have medias-
tinal tumors, but approximately 25% show significant parenchy-
mal infiltration of the lungs. 
Perhaps the most striking finding described by Uchiyama 
and co-workers is the geographic clustering of the patients' 
birth in the south of Japan. T hirteen of 16 patients reported 
were born in Kyushu, an island on which the city of Nagasaki 
is located. The role of atomic bombardment, and other environ-
mental or genetic factors, in the epidemiology of t his disease 
cannot be resolved at this time. 
The leukemic T cells from 3 of 6 patients with this Japanese 
T-cell syndrome appeared to act as suppressor cells [24]. That 
is, the leukemic cells inhibited immunoglobulin production by 
co-cultw-ed normal lymphocytes in the presence of pokeweed 
mitogen. (Cytoplasmic immunofluorescence was used to deter-
mine immunoglobulin production). Furthermore, supernatant 
fluids obtained from a short-term cul tw-e of leukemic cells of 1 
of these 3 patients showed a marked suppressive effect on the 
capacity of normal lymphocytes to produce immunoglobulins. 
T-IMMUNOREGULATORY NEOPLASMS 269 
This supernatant fluid did not appear to mediate the suppressor 
effect through a mechanism of direct cytotoxicity. The sup-
pressor effect was lost when the supernatant was heated at 
56°C for 30 min. Thus, in contrast to the immunoregulatory 
capacity found in certain patients with the Sezary syndrome, 
patients with the Japanese form of subacute adult T-cellleu-
kemia may have a neoplasm which originates from suppressor 
cells. 
Neoplastic Pro-Suppressor Cells from a Child with Acute 
Lymphoblastic Leukemia and Hypogammaglobulinemia 
We recently studied an infant boy with acute lymphoblastic 
leukemia who had hypogammaglobulinemia at initial presen-
tation [25]. Since 55% of the leukemic cells formed spontaneous 
rosettes with SRBCs and were killed with a horse anti-thymo-
cyte globulin plus complement, the neoplasm was classified as 
having aT-cell origin. One of the most striking featmes of this 
unusual child's disease was a profound depression of serum IgM 
and IgG concentrations. During treatment, the child received 
a number of drugs including hydroxyurea, vincristine, predni-
sone, daunorubicin, L-asparaginase, 6-mercaptopw·ine, metho-
trexate, and cyclophosphamide. The serum immunoglobulin 
levels rose during the course of treatment, and during the 
preterminal relapse of the leukemia there was once again a 
depression of serum IgM and IgG levels. When we first under-
took our study of this patient, we had data that the hypo-
gammaglobulinemia associated with a subset of patients with 
common variable immunodeficiency might be related to the 
presence of excessive suppressor T-cell activity [13]. Since the 
leukemic infant had depressed serum immunoglobulin levels at 
the time of diagnosis, and also while his leukemia was in 
terminal relapse, we conducted tests to determine whether his 
circulating neoplastic cells could suppress the immunoglobulin 
synthesis of co-cultured normal lymphocytes. We observed that 
the neoplastic lymphocytes from the patient profoundly de-
pressed immunoglobulin synthesis when cultmed with equal 
numbers of lymphocytes from 11 normal subjects tested. The 
suppression of normal immunoglobulin generally ranged from 
75% to 100% for the 3 classes of immunoglobulin (lgM, lgG, and 
IgA) tested. This neoplastic suppressor cell activity was nulli-
fied by prior exposme to 2000 rads of X-i.rradiation. 
We then asked whether the patient's leukemic cells could 
mediate suppression by themselves or whether they required 
the presence of cooperating normal T cells. As already dis-
cussed, in mice there are firm data to suggest that at least 2 
different T-cell subsets may be required for the generation of 
so-called suppressor effector T cells. The data in mice support 
the hypothesis that a so-called pro-suppressor (suppressor cell 
precmsor) subset must interact with a so-called suppressor 
activator (suppressor "amplifier") sub et before suppressor ef-
fector T cells can emerge. 
We addressed the question of a possible requirement forT-T 
interactions by taking advantage of the relative radioresistance 
of normal helper T cells and the relative radiosensitivity of 
normal suppressor T cells. There are extensive data in mice, 
and corroborating evidence in man, to support this concept. 
Therefore, by the use of radiation immediately before cultme 
it was possible to design experiments in which a T-cell popu-
lation retains helper activity with minimal interference from 
cells which might in some way be engaged in suppressor cell 
activity. Accordingly, we measured immunoglobulin production 
by B cells plus irradiated normal T cells in the presence of 
pokeweed mitogen. We reasoned that if the patient's circulating 
neoplastic T cells could mediate suppressor effects directly by 
themselves, they should be capable of inhibiting immunoglob-
ulin production by normal B cells cultured with either irradi-
ated or unirradiated normal T cells. On the other hand, if this 
patient's T cells had to interact with a cooperating subset of 
normal T cells before suppression could occm, they might be 
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expected to depress immunoglobulin secretion only w~en unir-
radiated normal T cells were present. When we d1d these 
experiments, we found that in a pokeweed mitogen-driven 
system of immunoglobulin secretion, neoplastic T cells from 
the patient caused suppression only when unirradiated normal 
T cells were provided [25]. In more recent experiments, we 
fou nd that t hese neoplastic T cells appear to function as a 
population of pro-suppressor T cells which can mature into 
suppressor effector T cells following interaction with a popula-
tion of normal suppressor activator T cells [26]. In some set-
tings, t he neoplastic pro-suppressor T cells could mature into 
fully functional suppressor effector T cells under the influence 
of a soluble factor(s) secreted by cooperating normal T cells. 
Based on our studies with these neoplastic pro-suppressor T 
cells, we have constructed a general hypothesis for the induction 
of human suppressor effector cells. In this hypothesis, human 
suppressor T cells have an interim existence as pro-suppressor 
cells. At this stage of maturation, such cells do not have signifi-
cant immunoregulatory capacity. U nder t he proper circum-
stances, pro-suppressor T cells may interact with a different set 
of activating T cells. This interaction could conceivably require 
direct surface membrane contact or could be mediated by 
soluble factors. It is likely that the pro-suppressor T cells must 
be capable of synthesizing DNA in order to mediate suppression 
fully. Once the pro-suppressor T-cell subset has differentiated 
into a suppressor effector T-cell subset, fur ther DNA synthesis 
is probably unnecessary for suppressor activity. . 
The hypothesis developed from the use of the leukemic cells 
with pro-suppressor T -cell properties provides at l eas~ 2 t~stable 
expectations for future clinical investigation. The first IS that 
neoplastic diseases representing proliferations at different steps 
in suppressor-cell differentiation will be discovered. ~xac~ly 
where the Japanese form of subacute T-cell leukemia with 
suppressor properties, described earlier in this paper, fits cannot 
be answered at this time. The second expectation is that those 
patients with a neoplasm composed largely of suppressor effec-
tor cells will very likely have hypogam maglobulmem1a directly 
related to their total tumor cell burden; however, t hose patients 
with a neoplasm of pro-suppressor cells or suppressor activator 
cells will very likely have hypogammaglobulinemia related ~o 
the residual number or functional capacity of non-neoplastic 
cooperating T cells, as well as their leukemic cells. In such 
patients, it should not be surprising to learn that th~ serum 
immunoglobulin levels may not bear a direct relationship to t he 
patient's neoplastic disease status and , indeed, may sometimes 
appear normal in spite of. strong in vitro evidence for suppressor 
activity. Finally, as an added complexity for future clinical 
investigation, the neoplastic cells from a patient with ataxia 
telangiectasia and aT-leukemia have recently been reported to 
mediate both helper and suppressor activity [27]. How neo-
plasms which express mixed immunoregulatory properties will 
affect host-immune status cannot be predicted at this time. 
Neoplastic thymic-derived suppressor cells have also been 
demonstrated in mice. The AKR strain of mice is noted for a 
very high incidence of spontaneous thymic lymphomas. There 
are recent data indicating that the neoplastic cells derived from 
mice bearing such lymphomas suppress the in vitro generation 
of humoral immune responses [28-31]. Suppression in t his 
system appears to require cell contact. In approximately 80% of 
the spontaneous lymphomas studied, a suppressor effect is 
observed only when syngeneic or semi-allogeneic target re-
sponder cells are used. In the remaining 20%, suppression is 
effective against both allogeneic and syngeneic target responder 
cells. A subset of th e AKR suppressor lymphoma cell popula-
tion appears to synthesize a form of su rface membrane-associ-
ated DNA and this cell-surface DNA is required for t he actual 
suppresso; effect of these neoplastic cells. The precise analogies 
between human and murine immunoregulatory T-cell neo-
plasms are topics for continued research. 
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SIGNIFICANCE OF IMMUNOREGULATORY 
NEOPLASMS TO CLINICAL AND BASIC 
INVESTIGATION 
The recognition that some T-ee~ leu~emias or lymphom~s 
may represent a homogeneous pr~hfer~t10? ofT ce.lls c~mmi~­
ted to either helper or suppressor fun ctton IS potent1all.y 1mpo1-
tant for a number of reasons. For example, certam forms of 
humoral immunodeficiency may be due to a helper- cell defect 
and not to intrinsically defective B cells a lone or excessively 
activated suppressor cells [13]. It is conceivable that neoplastic 
T-cell membrane-associated products or soluble factors re-
leased by neoplastic T cells could prove use.ful in the. treatment 
of selected thymic-deficiency states. Such ~actors 1?1ght. be the 
starting point for synthesis offactm:s useful m thy~mc-defJcJency 
states (or perhaps in t hose s it uatiOns where 1t IS desirable t? 
augment a normal immune response, e.g. , as ~art of Immum-
zations for overwhelming sepsis or even certam forms of canc~r) . 
N eoplastic T cells may be the startin~ immu~ogens wh1c.h 
could eventually make it possible to establish a ~·eliable serol~g Jc 
marker system for immunoregulatory subsets m man. In mice, 
as discussed earlier, an extremely useful cell-membrane-marker 
system exists. This marker system is referred to as the. Ly 
system of antigens, and depending on the Ly p~enotype of the 
T cells, it is possible to quantitate and selectively. ehmmate 
helper and suppressor T-cell subsets i.n mun?e splemc subpop-
ulations. Furthermore in mice there IS a defmed unmunoregu-
latory subregion of the' I portion of the maj?r h!stoc~mpatibility 
complex (H-2) [32]. This chromosomal regiOn IS design.ated I -J, 
and genes clustered within it may encode for certam .T-~e~l 
suppressor factors. These I -J-encoded produc.ts may mh1b1t 
both cellular and humoral immune responses m a number of 
systems. Furthermore, antisera rais~d . against I-J- ~ncoded 
products may actually increase ce rtam Immune reactiOns. In 
fact, such antisera raised against I -J-gene products may even 
promote tumor rejection in certa in murine systems, pre~umably 
by eliminating undesirable host suppressor cells that mterfere 
with effective immune responses dil'ected agamst tumor cells w 
vivo [33]. The overall concept t hat suppressor ce~s ~ay preve~t 
th e immune elimination of certain neoplasms IS discussed 111 
detail elsewhere [34]. 
The use of neoplastic human T cells with retained helper or 
suppressor function may speed the de~elo~ment of eit h.e r con-
ventional or so-called hybridoma ant1bodtes wh1ch might be 
used to classify the immunoregulatory function of human T 
cells in ana logy to the Ly and I -J systems of mice. Furthermore, 
we believe that it is realistic to anticipate the development of 
antisera which can tilt the immunoregulatory balance in favor 
of helper or suppressor activity in vivo ?epen~i~g on the cl0ical 
requirements of patients with a vanety of tmmunolog1cally 
related disorders. 
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DISCUSSION 
DR. FRI CK: Do t he Sezary cells a lso help the IgE system? 
DR. BROD ER: The Sezary helper activity would be very in terest ing 
to study in th e lgE system because serum IgE levels can be e levated to 
a n extraordinru·y degree in certa in patients with cutaneous T-cell 
lymphomas. We have not as yet adapted this system to determine 
whether in vitro lgE production is affected by Sezru·y cells. 
DR. TIGALAAH: The malignant T cells in Seza ry syndrome in genera l 
show h elper (viz-a-viz suppres ion) while the subacute T ce ll leukemia 
studied by Uchiyama, et a l. , in general behave as suppressors and not 
helpers . In contrast to the mru·ked tendency for the a typical ce Lls in 
mycosis fungoides-Sezary syndJ·ome to involve (invade) t he epidermis, 
t he cutaneous infil trates in subacute T ce ll leukemia a lmost invariably 
spares the epidermis. Would you speculate as to the potential inter -
re lationships of these observations in nonmaligna nt states-i.e., doe 
the epidermis have a specia l "attraction" for a subpopulation of normal 
T cells? 
Dn. BHODEH: I think, basically that th is would be tota lly speculative. 
I think you have out lined t he cl inical s igna ls that require further 
research. 
Dn. EDELSON: In part in a nswer to Bob T igelaar's question, we have 
now longitudinally foll owed patients with cmaneous T cell lymphoma 
a nd shown that progressive loss of epithelio t rophism by the neoplastic 
T ce Lls is seen as the disease becomes more agressive. This d iminished 
affini ty for epidermis is not a lway associated with loss of helper 
activity. What percentage of your patients with cutaneous T-cell lym-
phoma have now been shown to have neoplasms with polyclonal h eiper 
activity? 
DR. BnoDER: About 50%. I t ma.v be that idiotype pecific he lpers 
exist and we wou ld not detect them in ou1· te t svs tem. 
Dn. GoLDYNE: l s the helper T cell functio~ of th e Sezar.v cells 
dependent on solu ble prod ucts of those cells o r is it dependent on ce ll -
ce ll contact? 
Dn. BHODEH: One can get T-replacing helper facto r from norma l T 
cells under the right condi t ions, and on occasion we have seen a Sezary 
ce ll soluble factor which appeared to med iate a helper activi ty. It has, 
however, been hard to get results that coul d be reproduced from 
experiment to experiment. Maybe the fac tor is very lab ile. W e have 
even t ried storing our .fa tors in liqu id nitrogen. but it has still been 
hm·d to get reproducibili ty. 
Dn. STINGL: ls there . a correlat ion between type of lg- receptor 
expressed on ezary cells and t heir helper activity? 
Dn. BROD ER: The reason this question is being brough t up is because 
there have been reports that the capacity of T cells to express a 
receptor for the Fe port ion of IgM or lgG may be used to pred ict 
whether T cells will help or suppress respectively. In other words, those 
ce lls which have a receptor for the Fe or IgM have been viewed as 
helper cells and those cells which have a receptor for the Fe of IgG 
have been repor ted to mediate suppressor act ivity. T h e problem basi-
cally is that Werner P ichl er a nd I have shown that there is a transition 
between a cell t hat expresses the so-called IgG receptor to a ce ll which 
may express a n lgM receptor. The story has now become very compli -
cated. We do not see a direct correlation between those types of 
receptors a nd the polyc lona l helper act ivity we see. 
Dn. STINGL: Do Sezary cells express gene products encoded for by 
the HLA-D region? 
DR. BHODEH: Dean Mann has looked at HLA-D products and has 
found !a- like a nt igens on ce lls of certa in Sezary pa tients . Perhaps I 
should mention that neoplastic Sezary cells exhibit unusual HLA 
a ntigenic profil es when standard histocompatibility typing a lloant:i era 
ru·e used. 
